Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology.

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center Harvard Medical School. He was the professor of Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine proteome, protein interaction and related bioinformatics

Biomarker discovery in urine proteome, Protein interaction and related bioinformatics.

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program.

David I Smith got his B.S. From the University of Wisconsin in Madison in Mathematics and Molecular Biology. He then received his Ph.D. In Biochemistry;, also from UW, Madison. After postdoctoral research at Albert Einstein College of Medicine and the University of California, Irvine, he got his first faculty position at Wayne State University. In 1996 he joined the Mayo Clinic as a full professor in the Department of Laboratory Medicine and Pathology. He is currently the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at Mayo Clinic. His laboratory works on the characterization of the common fragile sites and also works to study the different roles that human papillomavirus plays in the development of cancer. His group uses the tools of next generation sequencing to address these questions.

His own research focuses on the different roles that human papillomavirus plays in the development of different cancers.

Charles J. Malemud received the Ph.D. from George Washington University in 1973 and completed postdoctoral studies at the State University of New York at Stony Brook in 1977. Since 1977, Dr. Malemud has been a member of the faculty at Case Western Reserve University School of Medicine where he is presently Professor of Medicine & Anatomy in the Division of Rheumatic Diseases and Senior Investigator in the Arthritis Research Laboratory. He has published more than 190 papers and reviews primarily in the field of chondrocyte biology. Professor Malemud is on the editorial board of several rheumatology, immunology and musculoskeletal journals and is Editor-in-Chief of the Journal of Clinical and Cellular Immunology. Close

Biology of the Musculoskeletal System, Intracellular Signal Transduction Pathways, Inflammation, Pro-inflammatory, Anti-Inflammatory &Anabolic Cytokines Apoptosis, Matrix Metalloproteinases, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia and Autoimmune Disorders

Dr. Sihem Bihorel (Ait-Oudhia) is an assistant professor at the Department of Pharmaceutics, University of Florida. Her laboratory is located at the Center for Pharmacometrics and Systems Pharmacology in Lake Nona, Orlando. In her research, Dr. Bihorel utilizes quantitative systems pharmacology approaches to guide the development of new therapies and the identification of promising combination therapies as well as of novel biomarkers in oncology. She integrates quantitative systems pharmacology with PK/PD modeling and simulation to advance drug discovery and development, and leverage the understanding of drugs action which holds great promise to facilitate translational research. Her research is also focused on investigating how priming solid tumors with pro-apoptotic agents enhances the deposition and efficacy of subsequent associated macromolecules and how these combination can be beneficial in defeating drug resistance in cancer. Prior to her current position, Dr. Bihorel was research assistant professor at the department of pharmaceutical sciences at the School of Pharmacy at the University at Buffalo (SUNY Buffalo). She also graduated with a PhD and was postdoctoral associate from the same.

Her research is also focused on investigating how priming solid tumors with pro-apoptotic agents enhances the deposition and efficacy of subsequent associated macromolecules and how these combination can be beneficial in defeating drug resistance in cancer.